MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted To Be 80%
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced that its product Ketamir-2, an oral formulation for depression treatment, has a predicted oral bioavailability of 80%. This is significantly higher than the current oral or intranasal absorption of ketamine. The company's lead developer highlighted the potential for Ketamir-2 to offer ease of administration and fewer side effects. IQVIA's analysis predicts that Ketamir-2 could generate an average annual sales of $3 billion by 2035, addressing the therapeutic gap in treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI). MIRA Pharmaceuticals is advancing clinical development and focusing on confirming the safety and efficacy of Ketamir-2.
November 29, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' announcement of Ketamir-2's high bioavailability and the potential $3 billion market by 2035 could significantly boost investor confidence and the company's stock price in the short term.
The positive results from the studies of Ketamir-2 and the substantial market potential forecasted by IQVIA are likely to be viewed favorably by investors. The news directly pertains to MIRA's core product and its future revenue prospects, which is critical for investor interest. The confidence score reflects the promising data and the reputable source of the market analysis, although the product is still in the pre-clinical stage and actual sales are yet to be realized.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100